574 related articles for article (PubMed ID: 19817806)
1. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies.
Wong M
Epilepsia; 2010 Jan; 51(1):27-36. PubMed ID: 19817806
[TBL] [Abstract][Full Text] [Related]
2. Developing Antiepileptogenic Drugs for Acquired Epilepsy: Targeting the Mammalian Target of Rapamycin (mTOR) Pathway.
Zeng LH; Rensing NR; Wong M
Mol Cell Pharmacol; 2009 Jan; 1(3):124-129. PubMed ID: 20419051
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic target of rapamycin (mTOR) in tuberous sclerosis complex-associated epilepsy.
Curatolo P
Pediatr Neurol; 2015 Mar; 52(3):281-9. PubMed ID: 25591831
[TBL] [Abstract][Full Text] [Related]
4. Intermittent dosing of rapamycin maintains antiepileptogenic effects in a mouse model of tuberous sclerosis complex.
Rensing N; Han L; Wong M
Epilepsia; 2015 Jul; 56(7):1088-97. PubMed ID: 26122303
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic role of mammalian target of rapamycin (mTOR) inhibition in preventing epileptogenesis.
McDaniel SS; Wong M
Neurosci Lett; 2011 Jun; 497(3):231-9. PubMed ID: 21354266
[TBL] [Abstract][Full Text] [Related]
6. Mammalian target of rapamycin (mTOR) pathways in neurological diseases.
Wong M
Biomed J; 2013; 36(2):40-50. PubMed ID: 23644232
[TBL] [Abstract][Full Text] [Related]
7. Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy.
Ryther RC; Wong M
Curr Neurol Neurosci Rep; 2012 Aug; 12(4):410-8. PubMed ID: 22544534
[TBL] [Abstract][Full Text] [Related]
8. Tuberous sclerosis complex as a model disease for developing new therapeutics for epilepsy.
Jeong A; Wong M
Expert Rev Neurother; 2016; 16(4):437-47. PubMed ID: 26854692
[TBL] [Abstract][Full Text] [Related]
9. The role of mTOR inhibitors in preventing epileptogenesis in patients with TSC: Current evidence and future perspectives.
Schubert-Bast S; Rosenow F; Klein KM; Reif PS; Kieslich M; Strzelczyk A
Epilepsy Behav; 2019 Feb; 91():94-98. PubMed ID: 29941212
[TBL] [Abstract][Full Text] [Related]
10. Role of mTOR inhibitors in epilepsy treatment.
Sadowski K; Kotulska-Jóźwiak K; Jóźwiak S
Pharmacol Rep; 2015 Jun; 67(3):636-46. PubMed ID: 25933981
[TBL] [Abstract][Full Text] [Related]
11. Animal models of focal cortical dysplasia and tuberous sclerosis complex: recent progress toward clinical applications.
Wong M
Epilepsia; 2009 Oct; 50 Suppl 9(0 9):34-44. PubMed ID: 19761452
[TBL] [Abstract][Full Text] [Related]
12. Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target.
Galanopoulou AS; Gorter JA; Cepeda C
Epilepsia; 2012 Jul; 53(7):1119-30. PubMed ID: 22578218
[TBL] [Abstract][Full Text] [Related]
13. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy.
Zeng LH; Rensing NR; Wong M
J Neurosci; 2009 May; 29(21):6964-72. PubMed ID: 19474323
[TBL] [Abstract][Full Text] [Related]
14. Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations.
Wong M
Exp Neurol; 2013 Jun; 244():22-6. PubMed ID: 22015915
[TBL] [Abstract][Full Text] [Related]
15. mTOR dysregulation and tuberous sclerosis-related epilepsy.
Curatolo P; Moavero R; van Scheppingen J; Aronica E
Expert Rev Neurother; 2018 Mar; 18(3):185-201. PubMed ID: 29338461
[TBL] [Abstract][Full Text] [Related]
16. Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.
Moavero R; Mühlebner A; Luinenburg MJ; Craiu D; Aronica E; Curatolo P
Epilepsy Behav; 2022 Jun; 131(Pt B):107713. PubMed ID: 33431351
[TBL] [Abstract][Full Text] [Related]
17. Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex.
Zhang B; McDaniel SS; Rensing NR; Wong M
PLoS One; 2013; 8(2):e57445. PubMed ID: 23437388
[TBL] [Abstract][Full Text] [Related]
18. Role of the mTOR signaling pathway in epilepsy.
Meng XF; Yu JT; Song JH; Chi S; Tan L
J Neurol Sci; 2013 Sep; 332(1-2):4-15. PubMed ID: 23773767
[TBL] [Abstract][Full Text] [Related]
19. mTOR Hyperactivity Levels Influence the Severity of Epilepsy and Associated Neuropathology in an Experimental Model of Tuberous Sclerosis Complex and Focal Cortical Dysplasia.
Nguyen LH; Mahadeo T; Bordey A
J Neurosci; 2019 Apr; 39(14):2762-2773. PubMed ID: 30700531
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Mammalian Target of Rapamycin for Epileptic Encephalopathies and Malformations of Cortical Development.
Jeong A; Wong M
J Child Neurol; 2018 Jan; 33(1):55-63. PubMed ID: 29246093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
